Allergic rhinitis (AR) is a common respiratory disease, and its prevalence is increasing all over the world, both in adults and in children. Patients experience symptoms that may negatively impact on physical, social and psychological well-being. Hence, if left untreated, allergic rhinitis may significantly affect quality of life. Under current guidelines, intranasal corticosteroids are considered the most effective drugs and they are recommended as first-line therapy. Among the several corticosteroid intranasal sprays available, beclomethasone dipropionate is one of the most prescribed. Recently, new intranasal hydrofluoroalkane-propelled formulations with little or no impact on the ozone layer have been developed for the treatment of AR. The use of these devices might improve patients' adherence to treatment, avoiding some of the most common side effects associated with aqueous formulations. This review provides the most recent evidence for the efficacy and safety of beclomethasone dipropionate hydrofluoroalkane nasal aerosol in the treatment of allergic rhinitis.
|Numero di pagine||10|
|Rivista||Expert Review of Clinical Immunology|
|Stato di pubblicazione||Published - 2016|
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
Ferrante, G., Malizia, V., Marchese, D., Montalbano, L., Cilluffo, G., & La Grutta, S. (2016). Beclomethasone dipropionate hydrofluoroalkane for the treatment of allergic rhinitis. Expert Review of Clinical Immunology, 12, 279-288.